Clinical trials: completed, sponsored by Celgene
Eosinophilic Gastroenteritis
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis
The purpose of this study is to evaluate the safety and efficacy of CC-93538 in adult and adolescent participants with eosinophilic gastroenteritis.
- Trial name
- NCT05214768
- Testing
- CC-93538
- Where
- 25 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Celgene
Multiple Myeloma
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone…
- Trial name
- POM MM 014 (NCT01946477)
- Testing
- Pomalidomide, Dexamethasone, Daratumumab
- Where
- 49 sites in United States, Canada and 2 more
- Volunteers
- 186 people
- Sponsor
- Celgene
Lymphoma, T-Cell
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
This study is a multicentric, open-label, randomized phase 3 trial. The study will be conducted in select countries in Europe and South Korea sponsored by LYSARC and in Japan sponsored by Celgene.
- Trial name
- NCT03703375
- Testing
- Azacitidine, Romidepsin, Gemcitabine
- Where
- 12 sites in Japan
- Volunteers
- 93 people
- Sponsor
- Celgene
Eosinophilic Esophagitis
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538.
- Trial name
- NCT04991935
- Testing
- CC-93538
- Where
- 167 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Celgene
Hematologic Neoplasm, Neoplasms
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Rollover study supporting hematological disorder indications from Celgene sponsored CC-486 (oral azacitidine) protocols eligible for participation in the study.
- Conditions
- Hematologic Neoplasm, Neoplasms, Hematologic Malignancies
- Trial name
- NCT02494258
- Testing
- CC-486
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Celgene
Ulcerative Colitis
An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
The purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis.
- Trial name
- NCT02531126
- Testing
- RPC1063
- Where
- 41 sites in United States, Australia and 18 more
- Volunteers
- 877 people
- Sponsor
- Celgene
Primary Myelofibrosis, Post-Polycythemia Vera
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis
- Trial name
- FREEDOM2 (NCT03952039)
- Testing
- FEDRATINIB, Best Available Therapy (BAT)
- Where
- 107 sites in Australia, Austria and 14 more
- Volunteers
- 202 people
- Sponsor
- Celgene
Lymphoma, Non-Hodgkin
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- TRANSFORM (NCT03575351)
- Testing
- Standard of Care, JCAR017
- Where
- 54 sites in United States, Belgium and 10 more
- Volunteers
- 184 people
- Sponsor
- Celgene
Lymphoma, Non-Hodgkin
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL.
- Trial name
- MAGNIFY (NCT01996865)
- Testing
- Lenalidomide, Rituximab
- Where
- 126 sites in United States, Germany and 1 more
- Volunteers
- 503 people
- Sponsor
- Celgene
Leukemia, Myeloid, Acute
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission
This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML), and who have achieved…
- Trial name
- QUAZAR AML-001 (NCT01757535)
- Testing
- Oral Azacitidine
- Where
- 223 sites in United States, Australia and 21 more
- Volunteers
- 472 people
- Sponsor
- Celgene
Multiple Myeloma
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma.
- Trial name
- KarMMa (NCT03361748)
- Testing
- bb2121
- Where
- 48 sites in United States, Belgium and 6 more
- Volunteers
- 149 people
- Sponsor
- Celgene
Leukemia, Myeloid, Isocitrate Dehydrogenase
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
This is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years or older with acute myeloid leukemia (AML)…
- Trial name
- IDHENTIFY (NCT02577406)
- Testing
- AG-221, BSC, Azacitidine
- Where
- 93 sites in United States, Australia and 16 more
- Volunteers
- 319 people
- Sponsor
- Celgene
Follicular Lymphoma
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available…
- Trial name
- RELEVANCE (NCT01476787)
- Testing
- Rituximab, Lenalidomide, Rituximab-CHOP
- Where
- 36 sites in United States, Japan
- Volunteers
- 1,030 people
- Sponsor
- Celgene
Non-Hodgkins Lymphoma
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Subjects who qualify will receive lenalidomide daily on days 1-21 of every 28-day cycle. Treatment will continue for up to 52 weeks or until disease progression; subjects who achieve a Complete Response (CR) will receive an…
- Trial name
- NCT00179673
- Testing
- Lenalidomide
- Where
- 15 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Celgene
Eosinophilic Esophagitis
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants…
- Trial name
- NCT04753697
- Testing
- CC-93538
- Where
- 212 sites in United States, Argentina and 13 more
- Volunteers
- 430 people
- Sponsor
- Celgene
Lymphoma, Non-Hodgkin, Lymphoma
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for…
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT03744676
- Testing
- lisocabtagene maraleucel
- Where
- 23 sites in United States
- Volunteers
- 104 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy
This study is designed to provide data on the immune response and safety of administering vaccines to relapsing multiple sclerosis (RMS) participants taking ozanimod compared to controls taking interferon-beta's or receiving no…
- Trial name
- NCT05028634
- Testing
- Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine
- Where
- 33 sites in United States, Germany
- Volunteers
- 63 people
- Sponsor
- Celgene
Neoplasms
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
This is a Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with small cell lung cancer or squamous non-small cell lung cancer who have…
- Trial name
- NCT04350463
- Testing
- CC-90011, Nivolumab
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 92 people
- Sponsor
- Celgene
Myelodysplastic Syndrome
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Evaluation of the Efficacy and Safety of Oral Azacitidine plus Best Supportive care versus Placebo and Best Supportive care in subjects with red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia due to…
- Trial name
- NCT01566695
- Testing
- Oral Azacitidine, Best Supportiv Care (BSC)
- Where
- 196 sites in United States, Australia and 21 more
- Volunteers
- 216 people
- Sponsor
- Celgene
Lymphoma, Non-Hodgkin
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
- Trial name
- TRANSCENDWORLD (NCT03484702)
- Testing
- JCAR017
- Where
- 20 sites in Austria, Belgium and 9 more
- Volunteers
- 113 people
- Sponsor
- Celgene